Poor adherence to placebo or amiodarone therapy predicts mortality: Results from the CAMIAT study
Poor adherence to placebo or amiodarone therapy predicts mortality: Results from the CAMIAT study
复制标题
DOI：
10.1097/00006842-199907000-00023
复制
发表时间：
1999-07-01
影响因子：
3.3
通讯作者：
Dorian, P
中科院分区：
文献类型：
--
作者：
Irvine, J;Baker, B;Dorian, P
目的：本研究探讨了依从性、死亡率和心理社会因素之间的关系。方法：受试者为参加加拿大胺碘酮心肌梗死心律失常试验的 1141 名患者。对研究药物（胺碘酮或安慰剂）的依从性较差，通过 2 年的药片计数来衡量，被定义为药片计数分布的第 20 个百分位数。还研究了依从性的预测因素，包括人口统计和心脏变量，以及在一部分参与者 (N = 671) 中抑郁、痛苦、敌意和社会支持的测量。结果：在控制心脏和人口统计学变量的生存分析中，安慰剂组和胺碘酮组依从性差与心源性猝死风险增加相关（相对风险 (RR) = 2.11，95% 置信区间 (CI) = 1.03-4.56，p
Objective: This study examined the relationship between adherence, mortality, and psychosocial factors. Methods: Subjects were 1141 patients participating in the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Poor adherence to study medication (amiodarone or placebo), measured by pill count over 2 years, was defined as the lower 20th percentile of the pill count distribution, Predictors of adherence were also studied and included demographic and cardiac variables and, in a subset of participants (N = 671), measures of depression, distress, hostility, and social support. Results: In survival analysis controlling for cardiac and demographic variables, poor adherence in the placebo and amiodarone groups was associated with an increased risk of sudden cardiac death (relative risk (RR) = 2.11, 95% confidence interval (CI) = 1.03-4.56, p